Clinical Trial Update: Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating pembrolizumab in combination with CA-4948 for progressive metastatic urothelial cancer, currently recruiting. The study target…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unresectable Urothelial Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• CA-4948
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 1 | Status: RECRUITING